UnicoCell Biomed CoTPE:6794 +4.67%83 Days Payable is 30.89 as of Dec. 2025, which is 41% below its 10-year median of 52.47. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 699 Biotechnology companies, UnicoCell Biomed Co ranks worse than 76.82% on this metric.
The historical rank and industry rank for UnicoCell Biomed Co's Days Payable or its related term are showing as below:
TPE:6794'
s Days Payable Range Over the Past 10 Years
Min: 27.73 Med: 52.47 Max: 318.04
Current: 35.69
During the past 9 years, UnicoCell Biomed Co's highest Days Payable was 318.04. The lowest was 27.73. And the median was 52.47.
TPE:6794's Days Payable is ranked worse than 76.82% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs TPE:6794: 35.69
UnicoCell Biomed Co's Days Payable
declined
from Dec. 2024 (57.67) to Dec. 2025 (30.89).
It may suggest that UnicoCell Biomed Coaccelerated paying its suppliers.
UnicoCell Biomed Co Days Payable Related Terms
UnicoCell Biomed Co Days Payable Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Days Payable distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
UnicoCell Biomed Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a Days Payable of 30.89 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on UnicoCell Biomed Co and its competitors. This is 41% below median its historical median of 52.47. Over the past decade, UnicoCell Biomed Co's Days Payable has ranged from 27.73 to 318.04. According to the industry distribution chart, UnicoCell Biomed Co ranks #537 out of 699 companies in the Biotechnology industry, placing it in the top 76.8%.
Is UnicoCell Biomed Co's Days Payable too high?
UnicoCell Biomed Co's current Days Payable of 30.89 is 41% below median its 10-year median of 52.47. Over the past 10 years, this metric has ranged from a low of 27.73 to a high of 318.04. The Biotechnology industry median Days Payable is 112.84. UnicoCell Biomed Co's value of 30.89 is 72.6% below this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #537 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #537 out of 699 companies for Days Payable. This places UnicoCell Biomed Co in the lower half of its industry. The industry median Days Payable is 112.84. UnicoCell Biomed Co's value of 30.89 is 72.6% below this benchmark. Historically, UnicoCell Biomed Co's own Days Payable has ranged from 27.73 to 318.04 over the past decade. While the company's 10-year median is 52.47 vs. the industry median of 112.84, UnicoCell Biomed Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Days Payable of 30.89 is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Days Payable is 30.89, which is 41% below median its own 10-year median of 52.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current Days Payable is 30.89, which is 41% below median its 10-year median of 52.47 and 72.6% below the Biotechnology industry median of 112.84. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Days Payable is 30.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
Days Payable: 30.89 (41% below median its 10-year median of 52.47)
GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
Industry Position: 72.6% below the Biotechnology median (#537 of 699)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
